ConforMIS (CFMS) Reports Q2 Loss of $2.51
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/10/2026
- S&P 500 ends down as oil tops $100 per barrel
- Trump promises $5,000 payout to U.S. adults if Republicans win election
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Rogers adds Sportsnet+ content to Xfinity TV packages for free
- AeroVironment (AVAV) Tops Q1 EPS by 29c, Offers Guidance
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
ConforMIS Reports Second Quarter 2015 Financial Results
August 11, 2015 7:30 AM EDTBEDFORD, Mass., Aug. 11, 2015 (GLOBE NEWSWIRE) -- ConforMIS, Inc. (NASDAQ: CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are customized to fit each patient's unique anatomy, announced today financial results for the second quarter ended June 30, 2015.
Recent Accomplishments & Highlights
Achieved total revenue of $19.2 million, including $3.5 million related to the settlement of patent litigation, up 72% year-over-year on a reported basis and up 81% year-over-year on a constant currency basis. Achieved product revenue of $15.8 million, up 41% year-over-year... MoreConforMIS Reports Second Quarter 2015 Financial Results
August 11, 2015 7:30 AM EDTBEDFORD, Mass., Aug. 11, 2015 (GLOBE NEWSWIRE) -- ConforMIS, Inc. (NASDAQ: CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are customized to fit each patient's unique anatomy, announced today financial results for the second quarter ended June 30, 2015.
Recent Accomplishments & Highlights
Achieved total revenue of $19.2 million, including $3.5 million related to the settlement of patent litigation, up 72% year-over-year on a reported basis and up 81% year-over-year on a constant currency basis. Achieved product revenue of $15.8 million, up 41% year-over-year... More